Zobrazeno 1 - 10
of 106
pro vyhledávání: '"Sven Stanzel"'
Autor:
Edith A. Perez, Sanne Lysbet de Haas, Wolfgang Eiermann, Carlos H. Barrios, Masakazu Toi, Young-Hyuck Im, Pier Franco Conte, Miguel Martin, Tadeusz Pienkowski, Xavier B. Pivot, Howard A. Burris, Sven Stanzel, Monika Patre, Paul Anthony Ellis
Publikováno v:
BMC Cancer, Vol 19, Iss 1, Pp 1-14 (2019)
Abstract Background The phase III EMILIA and TH3RESA trials demonstrated clinical benefits of trastuzumab emtansine (T-DM1) therapy in patients with previously treated HER2-positive metastatic breast cancer (MBC). Data from these and other trials sho
Externí odkaz:
https://doaj.org/article/09e852dddd5a43cfa17d3f82a5431f82
Autor:
Edith A. Perez, Sanne Lysbet de Haas, Wolfgang Eiermann, Carlos H. Barrios, Masakazu Toi, Young-Hyuck Im, Pier Franco Conte, Miguel Martin, Tadeusz Pienkowski, Xavier B. Pivot, Howard A. Burris, Sven Stanzel, Monika Patre, Paul Anthony Ellis
Publikováno v:
BMC Cancer, Vol 19, Iss 1, Pp 1-2 (2019)
Following publication of the original article [1], the authors reported the following errors in the article.
Externí odkaz:
https://doaj.org/article/690a5325d92f4fad952802d4d744779b
Autor:
Anita Appius, Jeffrey J. Pu, Antonio M. Risitano, Lilyan Wright, Guangsheng He, Talha Munir, Sasha Sreckovic, Sven Stanzel, Alexandre Sostelly, Alexander Roeth, Austin G. Kulasekararaj, Junichi Nishimura
Background Crovalimab is a novel anti-complement C5 antibody currently being studied as a treatment for paroxysmal nocturnal hemoglobinuria (PNH), a life-threatening disease associated with hemolytic anemia and thrombosis. Treatment with approved C5
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::915b9503c9c2b0673d8abec5cb7e23da
Autor:
Michel Ducreux, Andrew X. Zhu, Colby S. Shemesh, Ann-Lii Cheng, Sven Stanzel, Richard S. Finn, Coen Bernaards, Wendy Verret, Peter R. Galle, Alexandr Vilimovskij, Ning Ma
Publikováno v:
Cancer Research. 81:CT185-CT185
Background: Atezo + bev is the standard of care for pts with unresectable HCC and no prior systemic therapy. We report on post hoc exploratory analyses of the immune response to atezo and the impact assessment of ADAs on PK and clinical outcomes in t
Autor:
Sairy Hernandez, Ahmed Kaseb, S. Qin, Sven Stanzel, A-L Cheng, Vincent E. Gaillard, M. Villalobos, D-Z. Xu, Ning Ma, Peter R. Galle, Daneng Li, Andrew X. Zhu, V. Breder, H.Y. Lim, Richard S. Finn, Masafumi Ikeda, Philippe Merle, T-Y. Kim, Michel Ducreux, Masatoshi Kudo
Publikováno v:
Annals of Oncology. 31:S698-S699
Autor:
Monika Patre, Tadeusz Pienkowski, Masakazu Toi, Howard A. Burris, Wolfgang Eiermann, Young-Hyuck Im, Miguel Martin, Edith A. Perez, Pierfranco Conte, Sanne de Haas, Paul Ellis, Sven Stanzel, Xavier Pivot, Carlos H. Barrios
Publikováno v:
BMC Cancer, Vol 19, Iss 1, Pp 1-2 (2019)
Following publication of the original article [1], the authors reported the following errors in the article.
Autor:
Philip G. Hewitt, Germaine L. Truisi, Sven Stanzel, Konrad Moenks, Céline Parmentier, Lysiane Richert, Anja Wilmes, Alice Limonciel, Arno Lukas, Martin O. Leonard, Lydia Aschauer, Paul Jennings, Stefan O. Mueller, Annette Kopp-Schneider
Publikováno v:
Toxicology in Vitro. 30:7-18
High content omic methods provide a deep insight into cellular events occurring upon chemical exposure of a cell population or tissue. However, this improvement in analytic precision is not yet matched by a thorough understanding of molecular mechani
Autor:
Miguel Martin, Carlos H. Barrios, Monika Patre, Howard A. Burris, Pierfranco Conte, Edith A. Perez, Wolfgang Eiermann, Masakazu Toi, Xavier Pivot, Jennifer A. Petersen, Paul Ellis, Alexander Strasak, Sven Stanzel, Tadeusz Pienkowski, Young-Hyuck Im
Publikováno v:
Journal of Clinical Oncology
Purpose Trastuzumab and pertuzumab are human epidermal growth factor receptor 2 (HER2) –targeted monoclonal antibodies, and trastuzumab emtansine (T-DM1) is an antibody–drug conjugate that combines the properties of trastuzumab with the cytotoxic
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::27f8f0b4fee32fcd303e5c473782a16a
http://hdl.handle.net/11577/3219761
http://hdl.handle.net/11577/3219761
Autor:
Masakazu Toi, Sanne de Haas, Paul Anthony Ellis, Edith A. Perez, Tadeusz Pienkowski, Sven Stanzel, Wolfgang Eiermann, Miguel Martin, Pierfranco Conte, Monika Patre, Carlos H. Barrios, Young Hyuck Im, Howard A. Burris, Xavier Pivot
Publikováno v:
BMC Cancer
BMC Cancer, Vol 19, Iss 1, Pp 1-14 (2019)
BMC Cancer, Vol 19, Iss 1, Pp 1-14 (2019)
Background: The phase III EMILIA and TH3RESA trials demonstrated clinical benefits of trastuzumab emtansine (T-DM1) therapy in patients with previously treated HER2-positive metastatic breast cancer (MBC). Data from these and other trials showed that
Autor:
Jean Rommelaere, Zahari Raykov, Martina Schnölzer, Tiina Marttila, Marc Aprahamian, Antonio Marchini, Svitlana P. Grekova, Christiane Mougin, Séverine Valmary-Degano, Sven Stanzel, Junwei Li, Serena Bonifati, Georgi Hristov
Publikováno v:
EMBO Molecular Medicine
The rat parvovirus H-1PV has oncolytic and tumour-suppressive properties potentially exploitable in cancer therapy. This possibility is being explored and results are encouraging, but it is necessary to improve the oncotoxicity of the virus. Here we